H1 2026

Lars Bering, CEO
Allan Jeppesen, CFO

20 August 2026

SP Group Executive Board

Lars Bering
CEO

Søren Ulstrup
Executive Vice President

Allan Malmos Jeppesen
CFO

At a glance

Global manufacturer of plastics solutions

76%
customer-specific subsupplier projects

24%
own products

Global
footprint

35
factories

3,039
employees

18%
recycled plastics

SP Group's sales in H1 2026 broken down by product group:



SP Group – Advanced plastics solutions

Ergomat
Ergonomic solutions for industrial work environments

SP Medical
Guide wires for pharmaceutical use

TPI-Polytechniek
Components for livestock housing ventilation

MedicoPack
Packaging for the pharmaceutical industry

Nycopac
Industrial, recyclable plastic packaging. Both standard and customised solutions

SP Tinby
Reaction injection moulding, pultrusion and composite moulding of large plastic components

SP Moulding
Medium- and high-volume industrial injection moulding

SP Meditec
Injection moulding and blow moulding for the medical device industry

SP Gibo
Manufacturing of large plastic components by vacuum forming, rotational moulding and extrusion

Idé-Pro
Functional prototypes, injection moulding, high-pressure die casting of light metal components, EPS/EPP moulding and tool manufacturing

Kodaň Plast / Bovil
Plastic components manufactured by machining

Davinci 3D
Product development, engineering and 3D printing

Own products | Subsupplier projects

Global focus

SP GROUP

Geographic location of SP Group's companies and breakdown of global sales in 2025

Sales and production
- Denmark (15)
- Poland (6)
- China (2)
- USA (3)
- Latvia (1)
- Slovakia (2)
- Sweden (1)
- Finland (2)
- India (1)
- United Kingdom (2)

Sales and distribution
- Netherlands (1)
- Sweden (3)
- Canada (1)
- Norway (1)



Sales and production Sales and distribution

Highlights (1/2)

Record Q2 2026

- Revenue growth of **44.6%**
  - of which 29.4% organic growth
- EBITDA margin of **20.3%**
- EBT margin of **12.4%**

Record H1 2026

- Revenue growth of **32.9%**
  - of which 19.7% organic growth
- EBITDA margin of **20.3%**
- EBT margin of **12.7%**

- **Growth in own products and subsupplier projects**

Highlights 2/2

- **Expansion of medical device production in Poland**
- **Integration of Idé-Pro is in progress**
- **Acquisition of OGM Moulding Ltd.**

Outlook upgraded at 19 August 2026:

- Revenue growth of **24–30%**
- EBITDA margin of **19–21%**
- EBT margin of **11–13%**

Growth in sales of own products

SP GROUP

Revenue, own products
DKKm

+21.6%



Own products include pharmaceutical packaging, guide wires, livestock housing ventilation systems, maritime products, ergonomic solutions, etc.



Growth in subsupplier tasks

SP GROUP

Revenue, subsupplier projects
DKKm

+37.0%



Product groups, H1 2026

SP GROUP

Healthcare 35%

- Medical devices
- Pharmaceutical packaging
- Ergonomics and safety



Cleantech 29%

- Renewable energy
- Energy reduction
- Insulation products



Foodtech 14%

- Food industry
- Livestock housing ventilation
- Measuring equipment



Other 22%

- Automotive
- Maritime products
- Defence industry



Revenue in DKKm

Acquisition of OGM 1/3

STRENGTHS:

- Modern production facilities and a well-established platform in the United Kingdom
- Customers within medtech, safety equipment and transport
- Leading UK subsupplier of injection-moulded precision components
- Long-standing customer relationships
- Certified for demanding industries

About OGM Moulding Ltd.:

- Production in Oxfordshire and South Wales, United Kingdom
- 190 employees
- Injection moulding with a Box-Build concept, cleanroom production, prototyping and 3D metal printing


OGM, United Kingdom

Acquisition of OGM 2/3

STRATEGIC RATIONALE:

Medtech as a strategic growth area
Strengthens our position in one of the Group's most important growth areas and supports the One-Stop Shop strategy.

Box-Build – new capabilities
Sourcing, testing and assembly of electronic and plastic components – delivered, tested and fully packaged to the customer.

Bridgehead in the United Kingdom
A well-established platform in a market where the Group has not previously manufactured – serving UK customers locally at a time when demand is moving towards production closer to the markets.

Access to a strong technology region
Main factory in Oxfordshire, close to the universities of Oxford, Cambridge and London – a skilled workforce and a steady flow of development projects.

Global footprint for UK customers
OGM's customers gain access to SP Group's global production platform and can follow their customers outside the United Kingdom.

Complementary capabilities
Cleanroom production with relevant certifications, design for injection moulding, rapid prototyping and an in-house tool shop.

Acquisition of OGM 3/3

THE TRANSACTION

Purchase price: GBP 18.0m
Fixed purchase price (approx. DKK 158m)

Earn-out: Up to GBP 6.0m
Earn-out (approx. DKK 53m)
conditional on earnings in 2027 and 2028

EV/EBITDA approx. 4.8
Assuming full realisation of the earn-out


OGM, United Kingdom

Investment in Healthcare in Poland

Expansion of production in Poland:

- Focus on capacity, efficiency and space utilisation
- Conversion of 7,000 m^2 building for medical device production
- New 1,700 m^2 cleanroom facilities ready for production

Inauguration of SP Meditec's new cleanroom facilities in Poland

Financial highlights, Q2 2026 1/3

SP GROUP

Revenue
DKKm

+44.6%



EBITDA
DKKm

+59.9%



EBIT
DKKm

+86.4%



EBT
DKKm

+91.9%



Financial highlights, H1 2026 2/3

SP GROUP

Revenue
DKKm

+32.9%



EBITDA
DKKm

+36.2%



EBIT
DKKm

+45.4%



EBT
DKKm

+50.3%



Financial highlights, H1 2026 3/3

SP GROUP

Cash flows from operating activities increased by DKK 62 million
DKKm



Earnings per share, diluted, increased by 55.1%
DKK



Net interest-bearing debt (NIBD) decreased by DKK 119 million
DKKm



*The acquisition of Idé-Pro on 17 December 2025 resulted in a net increase in debt of DKK 653 million.

Equity increased by DKK 91 million
DKKm



Revenue performance



Revenue for 2026 is stated on a rolling 12-month basis

EBITDA and EBITDA margin performance



EBITDA for 2026 is stated on a rolling 12-month basis

EBITDA growth of 36.2% in H1 2026

- Margin improvement of 6.4 percentage points since 2016
- Margin improvement driven by:
  - Increased share of own products
  - Increased share of value chain
  - Production expansion in Eastern Europe
  - Automation

EBT and EBT margin performance



EBT for 2026 is stated on a rolling 12-month basis

EBT growth of 50.3% in H1 2026

- Margin improvement of 4.5 percentage points since 2016
- Margin improvement driven by:
  - Increased share of own products
  - Increased share of value chain
  - Production expansion in Eastern Europe
  - Automation

Key figures and financial ratios

DKKm	Q2 2026	Q2 2025	H1 2026	H1 2025	2025
Revenue	984	681	1,950	1,467	2,948
EBITDA	200	125	397	291	595
EBIT	140	75	280	192	398
EBT	122	64	248	165	345
EPS, diluted (DKK)			16.49	10.63	22.1
Equity			1,900	1,701	1,809
Cash flows from:					
- operating activities	132	98	291	229	393
- investing activities	-36	-26	-91	-84	-827
- financing activities	-68	-62	-145	-169	392
Change in cash and cash equivalents	27	10	54	-25	-41
NIBD			1,341	757	1,460
NIBD/EBITDA			1.9	1.3	2.4
Solvency ratio, %			46.0	54.6	45.3

Outlook for 2026

SP GROUP

The revenue guidance for 2026 is upgraded, while the guidance for earnings margins is maintained

	Original guidance at 25 March 2026	Updated guidance at 10 July 2026	Updated guidance at 19 August 2026
Revenue growth	**15–23%**	**22–28%**	**24–30%**
EBITDA margin	**19–21%**	**unchanged**	**unchanged**
EBT margin	**11–13%**	**unchanged**	**unchanged**

Summary

1. Strong organic growth in H1 2026
2. Growth in sales of own products and subsupplier projects
3. OGM Moulding Ltd.
4. Access to a new market and new customers in the United Kingdom
5. Full-year 2026 guidance upgraded

Q&A session

Further information:

Lars Bering
CEO

SP Group A/S
Snavevej 6-10
5471 Søndersø
Denmark

Tel.: +45 7023 2379 / +45 4033 8850
E-mail: lb@sp-group.dk